Jaguar health provides company updates and reports 2021 financials

Core 2022 development initiatives: ongoing operation of company's ontarget phase 3 clinical trial of crofelemer for prophylaxis of cancer therapy-related diarrhea (ctd) initiation and completion in 2h 2022 of investigator-initiated proof-of-concept study of crofelemer for short bowel syndrome with intestinal failure (sbs-if) fda conditional approval of canalevia™-ca1 for treatment of chemotherapy-induced diarrhea (cid) in dogs fourth quarter 2021 mytesi net revenue was approximately $2.1 million versus approximately $0.6 million in the third quarter of 2021, an increase of 230% reminder: jaguar to host investor webcast monday, march 14th at 8:30 a.m. eastern regarding 2021 financials and company updates; click here to register for webcast san francisco, ca / march 11, 2022 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today provided company updates and reported consolidated financial results for the year ended december 31, 2021.
JAGX Ratings Summary
JAGX Quant Ranking